Michele Morari - Publications

Affiliations: 
2012-2012 Medical Science Università di Ferrara, Ferrara, Emilia-Romagna, Italy 

113 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Domenicale C, Mercatelli D, Albanese F, Novello S, Vincenzi F, Varani K, Morari M. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice. Biomedicines. 10. PMID 35453631 DOI: 10.3390/biomedicines10040881  0.756
2022 Teil M, Dovero S, Bourdenx M, Arotcarena ML, Camus S, Porras G, Thiolat ML, Trigo-Damas I, Perier C, Estrada C, Garcia-Carrillo N, Morari M, Meissner WG, Herrero MT, Vila M, et al. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain : a Journal of Neurology. PMID 35285474 DOI: 10.1093/brain/awab374  0.528
2022 Albanese F, Domenicale C, Volta M, Morari M. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway. Biochemical Society Transactions. 50: 621-632. PMID 35225340 DOI: 10.1042/BST20211288  0.328
2022 Novello S, Mercatelli D, Albanese F, Domenicale C, Brugnoli A, D'Aversa E, Vantaggiato S, Dovero S, Murtaj V, Presotto L, Borgatti M, Shimshek DR, Bezard E, Moresco RM, Belloli S, ... Morari M, et al. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity. Neurobiology of Disease. 162: 105579. PMID 34871735 DOI: 10.1016/j.nbd.2021.105579  0.778
2021 Sarti AC, Vultaggio-Poma V, Falzoni S, Missiroli S, Giuliani AL, Boldrini P, Bonora M, Faita F, Di Lascio N, Kusmic C, Solini A, Novello S, Morari M, Rossato M, Wieckowski MR, et al. Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance. Function (Oxford, England). 2: zqab005. PMID 35330818 DOI: 10.1093/function/zqab005  0.7
2021 Albanese F, Mercatelli D, Finetti L, Lamonaca G, Pizzi S, Shimshek DR, Bernacchia G, Morari M. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo. Neurobiology of Disease. 159: 105487. PMID 34419621 DOI: 10.1016/j.nbd.2021.105487  0.31
2021 Viaro R, Longo F, Vincenzi F, Varani K, Morari M. L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. Brain Research. 147583. PMID 34284020 DOI: 10.1016/j.brainres.2021.147583  0.6
2021 Regoni M, Zanetti L, Comai S, Mercatelli D, Novello S, Albanese F, Croci L, Consalez GG, Ciammola A, Valtorta F, Morari M, Sassone J. Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse. Biomedicines. 9. PMID 34063112 DOI: 10.3390/biomedicines9050514  0.762
2021 Pischedda F, Cirnaru MD, Ponzoni L, Sandre M, Biosa A, Carrion MP, Marin O, Morari M, Pan L, Greggio E, Bandopadhyay R, Sala M, Piccoli G. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation. Brain : a Journal of Neurology. PMID 33876242 DOI: 10.1093/brain/awab073  0.319
2020 Regoni M, Cattaneo S, Mercatelli D, Novello S, Passoni A, Bagnati R, Davoli E, Croci L, Consalez GG, Albanese F, Zanetti L, Passafaro M, Serratto GM, Di Fonzo A, Valtorta F, ... ... Morari M, et al. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity. Cell Death & Disease. 11: 963. PMID 33173027 DOI: 10.1038/s41419-020-03172-8  0.762
2020 Brugnoli A, Pisanò CA, Morari M. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats. Neurobiology of Disease. 144: 105044. PMID 32798726 DOI: 10.1016/J.Nbd.2020.105044  0.444
2020 Belloli S, Morari M, Murtaj V, Valtorta S, Moresco RM, Gilardi MC. Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation. Frontiers in Aging Neuroscience. 12: 152. PMID 32581765 DOI: 10.3389/Fnagi.2020.00152  0.404
2020 Vegas-Suárez S, Pisanò CA, Requejo C, Bengoetxea H, Lafuente JV, Morari M, Miguelez C, Ugedo L. 6-hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata. British Journal of Pharmacology. PMID 32464686 DOI: 10.1111/Bph.15145  0.324
2020 Bourdenx M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, Thiolat ML, Rougier NP, Prigent A, Aubert P, Bohic S, Sandt C, Laferrière F, Doudnikoff E, Kruse N, ... ... Morari M, et al. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Science Advances. 6: eaaz9165. PMID 32426502 DOI: 10.1126/Sciadv.Aaz9165  0.771
2020 Pisanò CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, Vailati S, Padoani G, Morari M. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease. Neuropharmacology. 167: 108006. PMID 32086070 DOI: 10.1016/J.Neuropharm.2020.108006  0.77
2020 Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Marti M, Mercatelli D, Pisanò CA, Brugnoli A, Morari M, Zaveri NT. Discovery and Structure-activity Relationships of Nociceptin Receptor Partial Agonists that Afford Symptom Ablation in Parkinson's Disease Models. Journal of Medicinal Chemistry. PMID 31951130 DOI: 10.1021/Acs.Jmedchem.9B02134  0.413
2019 Albanese F, Novello S, Morari M. Autophagy and LRRK2 in the Aging Brain. Frontiers in Neuroscience. 13: 1352. PMID 31920513 DOI: 10.3389/Fnins.2019.01352  0.753
2019 Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M. Managing Parkinson's disease: Moving ON with NOP. British Journal of Pharmacology. PMID 31648371 DOI: 10.1111/Bph.14893  0.633
2019 Mazzocchi M, Wyatt SL, Mercatelli D, Morari M, Morales-Prieto N, Collins LM, Sullivan AM, O'Keeffe GW. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Frontiers in Cell and Developmental Biology. 7: 191. PMID 31572723 DOI: 10.3389/Fcell.2019.00191  0.368
2019 Mercatelli D, Bolognesi P, Frassineti M, Pisanò CA, Longo F, Shimshek DR, Morari M. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacology Research & Perspectives. 7: e00484. PMID 31149340 DOI: 10.1002/Prp2.484  0.694
2019 Mercatelli D, Pisanò CA, Novello S, Morari M. NOP Receptor Ligands and Parkinson's Disease. Handbook of Experimental Pharmacology. PMID 30689087 DOI: 10.1007/164_2018_199  0.786
2018 Russo I, Di Benedetto G, Kaganovich A, Ding J, Mercatelli D, Morari M, Cookson MR, Bubacco L, Greggio E. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. Journal of Neuroinflammation. 15: 297. PMID 30368241 DOI: 10.1186/S12974-018-1337-8  0.662
2018 Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C. Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia. The Journal of Pharmacology and Experimental Therapeutics. PMID 30291173 DOI: 10.1124/jpet.118.251645  0.767
2018 Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice. Neurobiology of Disease. PMID 30172844 DOI: 10.1016/J.Nbd.2018.08.018  0.791
2018 Tozzi A, Durante V, Bastioli G, Mazzocchetti P, Novello S, Mechelli A, Morari M, Costa C, Mancini A, Di Filippo M, Calabresi P. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. Neurobiology of Disease. PMID 29908325 DOI: 10.1016/J.Nbd.2018.06.008  0.792
2018 Tozzi A, Tantucci M, Marchi S, Mazzocchetti P, Morari M, Pinton P, Mancini A, Calabresi P. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease. Cell Death & Disease. 9: 204. PMID 29434188 DOI: 10.1038/S41419-017-0221-2  0.463
2017 Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M. Antiparkinsonian and antidyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. British Journal of Pharmacology. PMID 29232769 DOI: 10.1111/Bph.14123  0.748
2017 Morari M, Brugnoli A, Pisano CA, Novello S, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M. Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. The Journal of Pharmacology and Experimental Therapeutics. PMID 29167350 DOI: 10.1124/Jpet.117.245100  0.764
2017 Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, et al. Role of LRRK2 in the regulation of dopamine receptor trafficking. Plos One. 12: e0179082. PMID 28582422 DOI: 10.1371/Journal.Pone.0179082  0.467
2017 Sacchi S, Novellis V, Paolone G, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassineti M, Bertolino A, Pollegioni L, Morari M, Maione S, et al. Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. Scientific Reports. 7: 46288. PMID 28393897 DOI: 10.1038/Srep46288  0.382
2017 Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications. 5: 22. PMID 28292328 DOI: 10.1186/S40478-017-0426-8  0.796
2017 Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P. Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28128334 DOI: 10.1038/Npp.2017.20  0.576
2016 Arcuri L, Mercatelli D, Morari M. Parkinson's disease: no NOP, new hope. Oncotarget. PMID 28086211 DOI: 10.18632/Oncotarget.13710  0.323
2016 Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/J.Nbd.2016.01.016  0.754
2016 Melloni E, Brugnoli A, Caccia C, Morari M, Padoani G, Vailati S, Sardina M. Safinamide and glutamate release: New insights Parkinsonism & Related Disorders. 22: e177. DOI: 10.1016/J.Parkreldis.2015.10.439  0.406
2016 Morari M, Brugnoli A, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M. Safinamide differentially modulates glutamate release in the basal ganglia nuclei Parkinsonism & Related Disorders. 22: e176-e177. DOI: 10.1016/J.Parkreldis.2015.10.438  0.335
2015 Collins LM, Dal Bo G, Calcagno M, Monzón-Sandoval J, Sullivan AM, Gutierrez H, Morari M, O'Keeffe GW. Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism. Molecular Neurobiology. PMID 26687234 DOI: 10.1007/S12035-015-9611-6  0.387
2015 Brugnoli A, Napolitano F, Usiello A, Morari M. Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia. Neurobiology of Disease. 85: 155-163. PMID 26522958 DOI: 10.1016/J.Nbd.2015.10.020  0.47
2015 Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, et al. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. Parkinsonism & Related Disorders. 21: 1156-63. PMID 26282470 DOI: 10.1016/J.Parkreldis.2015.07.025  0.705
2015 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, ... ... Morari M, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/J.Pneurobio.2015.07.002  0.537
2015 Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26207892 DOI: 10.1002/Mds.26326  0.396
2015 Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR. Selectivity and Anti-Parkinson's Potential of Thiadiazolidinone RGS4 Inhibitors. Acs Chemical Neuroscience. 6: 911-9. PMID 25844489 DOI: 10.1021/Acschemneuro.5B00063  0.383
2015 Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, et al. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. Neurobiology of Aging. 36: 1890-902. PMID 25771393 DOI: 10.1016/J.Neurobiolaging.2015.02.003  0.599
2015 Morari M, Fantin M. Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease. The Analyst. 140: 3830-9. PMID 25584655 DOI: 10.1039/C4An01918K  0.417
2015 Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science & Engineering. C, Materials For Biological Applications. 48: 294-300. PMID 25579926 DOI: 10.1016/J.Msec.2014.12.014  0.625
2015 Piccoli G, Pischedda F, Cirnaru D, Greggio E, Onofri F, Russo I, Marte A, Belluzzi E, Morari M, Joannes Gloeckner C, Perego C, Marsicano S. LRRK2 modulates neuronal vesicles cycle through protein interactions Springerplus. 4. DOI: 10.1186/2193-1801-4-S1-P35  0.352
2014 Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 12953-62. PMID 25253844 DOI: 10.1523/Jneurosci.4677-13.2014  0.444
2014 Longo F, Russo I, Shimshek DR, Greggio E, Morari M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease. 71: 62-73. PMID 25107341 DOI: 10.1016/J.Nbd.2014.07.013  0.633
2014 Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience. 7: 49. PMID 24904275 DOI: 10.3389/Fnmol.2014.00049  0.697
2014 Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific Reports. 4: 3730. PMID 24429495 DOI: 10.1038/Srep03730  0.573
2013 Viaro R, Calcagno M, Marti M, Borrelli E, Morari M. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands. Neuropharmacology. 72: 126-38. PMID 23643745 DOI: 10.1016/J.Neuropharm.2013.04.046  0.426
2013 Mabrouk OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A, Parsons CG, Auberson YP, Morari M. GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. Acs Chemical Neuroscience. 4: 808-16. PMID 23611155 DOI: 10.1021/Cn400016D  0.429
2013 Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111. British Journal of Pharmacology. 168: 863-79. PMID 22994368 DOI: 10.1111/J.1476-5381.2012.02219.X  0.343
2012 Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 16106-19. PMID 23152595 DOI: 10.1523/Jneurosci.6408-11.2012  0.593
2012 Morari M. L-dopa impairs proteasome activity in Parkinsonism through D1 dopamine receptor. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 706. PMID 22822491 DOI: 10.1002/Mds.24961  0.416
2012 Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain : a Journal of Neurology. 135: 1884-99. PMID 22561640 DOI: 10.1093/Brain/Aws101  0.388
2012 Buzzi A, Chikhladze M, Falcicchia C, Paradiso B, Lanza G, Soukupova M, Marti M, Morari M, Franceschetti S, Simonato M. Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiology of Disease. 47: 216-24. PMID 22538221 DOI: 10.1016/J.Nbd.2012.04.005  0.325
2012 Mela F, Marti M, Bido S, Cenci MA, Morari M. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiology of Disease. 45: 573-82. PMID 22001605 DOI: 10.1016/J.Nbd.2011.09.015  0.408
2011 Bido S, Marti M, Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. Journal of Neurochemistry. 118: 1043-55. PMID 21740438 DOI: 10.1111/J.1471-4159.2011.07376.X  0.417
2011 Fantin M, Morari M, Tison F, Fernagut PO. NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid. Neurological Research. 33: 444-7. PMID 21535946 DOI: 10.1179/1743132810Y.0000000002  0.38
2011 Viaro R, Morari M, Franchi G. Progressive motor cortex functional reorganization following 6-hydroxydopamine lesioning in rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 4544-54. PMID 21430155 DOI: 10.1523/Jneurosci.5394-10.2011  0.345
2011 Volta M, Viaro R, Trapella C, Marti M, Morari M. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Experimental Neurology. 228: 126-37. PMID 21215744 DOI: 10.1016/J.Expneurol.2010.12.024  0.451
2010 Volta M, Mabrouk OS, Bido S, Marti M, Morari M. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. Journal of Neurochemistry. 115: 1543-55. PMID 20950413 DOI: 10.1111/J.1471-4159.2010.07061.X  0.454
2010 Marti M, Sarubbo S, Latini F, Cavallo M, Eleopra R, Biguzzi S, Lettieri C, Conti C, Simonato M, Zucchini S, Quatrale R, Sensi M, Candeletti S, Romualdi P, Morari M. Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1723-32. PMID 20589874 DOI: 10.1002/Mds.23271  0.382
2010 Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C, Morari M. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). Peptides. 31: 1194-204. PMID 20307605 DOI: 10.1016/J.Peptides.2010.03.015  0.405
2010 Viaro R, Marti M, Morari M. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade. Experimental Neurology. 223: 473-84. PMID 20122926 DOI: 10.1016/J.Expneurol.2010.01.014  0.448
2010 Mabrouk OS, Marti M, Morari M. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice. Neuroscience. 166: 40-8. PMID 20006677 DOI: 10.1016/J.Neuroscience.2009.12.006  0.455
2010 Mela F, Millan MJ, Brocco M, Morari M. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. Neuropharmacology. 58: 528-36. PMID 19733554 DOI: 10.1016/J.Neuropharm.2009.08.017  0.382
2009 Mabrouk OS, Marti M, Salvadori S, Morari M. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience. 164: 360-9. PMID 19729051 DOI: 10.1016/J.Neuroscience.2009.08.058  0.405
2009 Marti M, Viaro R, Guerrini R, Franchi G, Morari M. Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 341-55. PMID 18418358 DOI: 10.1038/Npp.2008.56  0.316
2008 Mabrouk OS, Volta M, Marti M, Morari M. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism. Journal of Neurochemistry. 107: 1647-59. PMID 19094058 DOI: 10.1111/J.1471-4159.2008.05727.X  0.458
2008 Marti M, Trapella C, Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. Journal of Neurochemistry. 107: 1683-96. PMID 19014386 DOI: 10.1111/J.1471-4159.2008.05735.X  0.444
2008 Fantin M, Auberson YP, Morari M. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism. Journal of Neurochemistry. 106: 957-68. PMID 18435828 DOI: 10.1111/J.1471-4159.2008.05439.X  0.438
2008 Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiology of Disease. 30: 430-8. PMID 18413287 DOI: 10.1016/J.Nbd.2008.02.011  0.427
2007 Fantin M, Marti M, Auberson YP, Morari M. NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways. Journal of Neurochemistry. 103: 2200-11. PMID 17986236 DOI: 10.1111/J.1471-4159.2007.04966.X  0.424
2007 Fantin M, Fischetti C, Trapella C, Morari M. Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways. British Journal of Pharmacology. 152: 549-55. PMID 17618307 DOI: 10.1038/Sj.Bjp.0707377  0.353
2007 Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Journal of Neurochemistry. 101: 483-97. PMID 17359492 DOI: 10.1111/J.1471-4159.2007.04456.X  0.448
2007 Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. The Journal of Pharmacology and Experimental Therapeutics. 321: 961-7. PMID 17329552 DOI: 10.1124/Jpet.106.116764  0.357
2007 Marti M, Trapella C, Viaro R, Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 1297-307. PMID 17287504 DOI: 10.1523/Jneurosci.4346-06.2007  0.42
2006 Mela F, Marti M, Fiorentini C, Missale C, Morari M. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Molecular and Cellular Neurosciences. 31: 284-92. PMID 16249096 DOI: 10.1016/J.Mcn.2005.09.016  0.393
2006 Marti M, Mela F, Fantin M, Viaro R, Morari M. S5 NOVEL THERAPEUTIC STRATEGIES FOR TREATMENT OF MOTOR ABNORMALITIES IN PARKINSON??S DISEASE: FOCUS ON OPIOID RECEPTORS Behavioural Pharmacology. 17: 536. DOI: 10.1097/00008877-200609000-00024  0.368
2005 Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, ... Morari M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9591-601. PMID 16237164 DOI: 10.1523/Jneurosci.2546-05.2005  0.515
2005 Marti M, Manzalini M, Fantin M, Bianchi C, Della Corte L, Morari M. Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine. Journal of Neurochemistry. 93: 195-205. PMID 15773919 DOI: 10.1111/J.1471-4159.2005.03015.X  0.449
2005 Carrà G, Rizzi A, Guerrini R, Barnes TA, McDonald J, Hebbes CP, Mela F, Kenigs VA, Marzola G, Rizzi D, Gavioli E, Zucchini S, Regoli D, Morari M, Salvadori S, et al. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. The Journal of Pharmacology and Experimental Therapeutics. 312: 1114-23. PMID 15509719 DOI: 10.1124/Jpet.104.077339  0.358
2004 Marti M, Mela F, Guerrini R, Calò G, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. Journal of Neurochemistry. 91: 1501-4. PMID 15584926 DOI: 10.1111/J.1471-4159.2004.02843.X  0.46
2004 Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 6659-66. PMID 15282268 DOI: 10.1523/Jneurosci.0987-04.2004  0.461
2004 Mela F, Marti M, Ulazzi L, Vaccari E, Zucchini S, Trapella C, Salvadori S, Beani L, Bianchi C, Morari M. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. The European Journal of Neuroscience. 19: 1317-24. PMID 15016089 DOI: 10.1111/J.1460-9568.2004.03220.X  0.37
2004 Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M, Bernardi G, Calabresi P. Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Molecular and Cellular Neurosciences. 25: 9-20. PMID 14962736 DOI: 10.1016/J.Mcn.2003.09.013  0.397
2003 Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C, Morari M. Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. The European Journal of Neuroscience. 18: 759-67. PMID 12925002 DOI: 10.1046/J.1460-9568.2003.02806.X  0.361
2003 Marti M, Paganini F, Stocchi S, Mela F, Beani L, Bianchi C, Morari M. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. Journal of Neurochemistry. 84: 792-802. PMID 12562523 DOI: 10.1046/J.1471-4159.2003.01569.X  0.432
2003 Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calo' G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C, Morari M. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. British Journal of Pharmacology. 138: 91-8. PMID 12522077 DOI: 10.1038/Sj.Bjp.0705005  0.337
2002 Marti M, Mela F, Bianchi C, Beani L, Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. Journal of Neurochemistry. 83: 635-44. PMID 12390525 DOI: 10.1046/J.1471-4159.2002.01169.X  0.436
2002 Marti M, Guerrini R, Beani L, Bianchi C, Morari M. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience. 112: 153-60. PMID 12044480 DOI: 10.1016/S0306-4522(02)00050-7  0.408
2002 Calo G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, Marzola G, Marti M, McDonald J, Morari M, Lambert DG, Salvadori S, Regoli D. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. British Journal of Pharmacology. 136: 303-11. PMID 12010780 DOI: 10.1038/Sj.Bjp.0704706  0.366
2002 Pisani A, Bonsi P, Catania MV, Giuffrida R, Morari M, Marti M, Centonze D, Bernardi G, Kingston AE, Calabresi P. Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons The Journal of Neuroscience. 22: 6176-6185. DOI: 10.1523/Jneurosci.22-14-06176.2002  0.39
2001 Marti M, Paganini F, Stocchi S, Bianchi C, Beani L, Morari M. Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release. The European Journal of Neuroscience. 14: 1181-4. PMID 11683911 DOI: 10.1046/J.0953-816X.2001.01750.X  0.397
2000 Schlicker E, Morari M. Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides. 21: 1023-9. PMID 10998536 DOI: 10.1016/S0196-9781(00)00233-3  0.444
2000 Sbrenna S, Marti M, Morari M, Calo' G, Guerrini R, Beani L, Bianchi C. Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. British Journal of Pharmacology. 130: 425-33. PMID 10807682 DOI: 10.1038/Sj.Bjp.0703321  0.306
2000 Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L, Morari M. Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. The European Journal of Neuroscience. 12: 1848-50. PMID 10792462 DOI: 10.1046/J.1460-9568.2000.00081.X  0.458
1999 Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L, Morari M. In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats. Journal of Neurochemistry. 72: 875-8. PMID 9930765 DOI: 10.1046/J.1471-4159.1999.720875.X  0.406
1999 Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochemistry International. 33: 383-97. PMID 9874089 DOI: 10.1016/S0197-0186(98)00052-7  0.47
1998 Morari M, Sbrenna S, Marti M, Caliari F, Bianchi C, Beani L. NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms. Journal of Neurochemistry. 71: 2006-17. PMID 9798925 DOI: 10.1046/J.1471-4159.1998.71052006.X  0.347
1998 Morari M, Sbrenna S, Marti M, O'Connor WT, Bianchi C, Fuxe K, Beani L. Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. The European Journal of Neuroscience. 10: 1716-22. PMID 9751143 DOI: 10.1046/J.1460-9568.1998.00176.X  0.368
1996 Morari M, O'Connor WT, Ungerstedt U, Bianchi C, Fuxe K. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat--II. Evidence for striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. Neuroscience. 72: 89-97. PMID 8730708 DOI: 10.1016/0306-4522(95)00556-0  0.441
1996 Morari M, O'Connor WT, Darvelid M, Ungerstedt U, Bianchi C, Fuxe K. Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat--I. Effects of perfusion with tetrodotoxin and low-calcium medium. Neuroscience. 72: 79-87. PMID 8730707 DOI: 10.1016/0306-4522(95)00557-9  0.404
1995 Morari M, Calo G, Ferraro L, Fabrizi A, Acciarri N, Piazza G, Bianchi C, Beani L. AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices. Neurochemistry International. 26: 77-83. PMID 7540466 DOI: 10.1016/0197-0186(94)00099-G  0.35
1994 Morari M, Menegale M, Caló G, Ferraro L, Tomasini C, Bianchi C, Beani L. Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. Neurochemistry International. 24: 191-200. PMID 8161946 DOI: 10.1016/0197-0186(94)90106-6  0.302
1994 Morari M, O'Connor WT, Ungerstedt U, Fuxe K. Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. European Journal of Pharmacology. 256: 23-30. PMID 7913045 DOI: 10.1016/0014-2999(94)90611-4  0.442
1993 Morari M, O'Connor WT, Ungerstedt U, Fuxe K. N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study. Journal of Neurochemistry. 60: 1884-93. PMID 8097237 DOI: 10.1111/J.1471-4159.1993.Tb13416.X  0.397
1992 Fuxe K, Janson AM, Rosén L, Finnman UB, Tanganelli S, Morari M, Goldstein M, Agnati LF. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Experimental Brain Research. 88: 117-130. PMID 1347270 DOI: 10.1007/Bf02259133  0.417
1991 Tanganelli S, Antonelli T, Morari M, Bianchi C, Beani L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neuroscience Letters. 122: 270-2. PMID 2027527 DOI: 10.1016/0304-3940(91)90875-T  0.373
1991 Morari M, Calo G, Antonelli T, Gaist G, Acciarri N, Fabrizi A, Bianchi C, Beani L. Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex. Brain Research. 553: 14-7. PMID 1834301 DOI: 10.1016/0006-8993(91)90223-I  0.318
1991 Beani L, Tanganelli S, Antonelli T, Ferraro L, Morari M, Spalluto P, Nordberg A, Bianchi C. Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. British Journal of Pharmacology. 104: 15-20. PMID 1664759 DOI: 10.1111/J.1476-5381.1991.Tb12377.X  0.312
Show low-probability matches.